Alzheimer's Disease: Defusing The Bomb By 2025
The number of drug candidates in development for Alzheimer's is at its highest-ever level and despite the lack of success to date, biopharma companies continue to believe the potential rewards are worth the risk. As R&D in the field accelerates, therapies that treat not only symptoms of the disease but also slow its progression are expected to arrive sooner rather than later.
You may also be interested in...
Alzheimer’s Update: Amyloid Hypothesis Lives On At Biogen, Lilly, Merck, Pfizer, Roche
Biogen rose and fell based on the company’s latest aducanumab results, but the Clinical Trials on Alzheimer’s Disease meeting Dec. 8-10 showed that regardless of Lilly’s Phase III solanezumab failure, companies continue to invest in amyloid and other hypotheses, including BACE, gamma secretase and other programs.
Immunotherapies Set To Spark Alzheimer's Drug Market
Five late-stage Alzheimer's disease candidates, three of them monoclonal antibodies, are projected to rack up big sales when they launch, according to a new report by Datamonitor Healthcare. Like the rest of the AD drug market, growth for these products will come from treating earlier stages of the disease (article free with registration).
TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study
While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.